Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $429.60 – a decrease of 14.28% over the previous week. Vertex Pharmaceuticals employs 6,100 staff and has a trailing 12-month revenue of around $11 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $429.60 |
|---|---|
| 52-week range | $377.85 - $519.88 |
| 50-day moving average | $492.05 |
| 200-day moving average | $471.51 |
| Wall St. target price | $500.32 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $434.82 from 2025-05-07
| 1 week (2025-05-02) | -13.24% |
|---|---|
| 1 month (2025-04-10) | -8.55% |
| 3 months (2025-02-10) | -7.48% |
| 6 months (2024-11-08) | -15.85% |
| 1 year (2024-05-10) | 2.85% |
|---|---|
| 2 years (2023-05-09) | 26.10% |
| 3 years (2022-05-09) | 85.01% |
| 5 years (2020-05-08) | 60.08% |
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.374. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.8 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $11 billion |
|---|---|
| Operating margin TTM | 44.98% |
| Gross profit TTM | $6 billion |
| Return on assets TTM | 12.68% |
| Return on equity TTM | -3.15% |
| Profit margin | -4.86% |
| Book value | $63.87 |
| Market Capitalization | $128.8 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
Vertex Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 30.84 |
|---|---|
| Total ESG percentile | 44 |
| Environmental score | 5.65 |
| Environmental score percentile | 8 |
| Social score | 24.22 |
| Social score percentile | 8 |
| Governance score | 12.46 |
| Governance score percentile | 8 |
| Level of controversy | 2 |
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Vertex Pharmaceuticals's shares were split on a 2:1 basis on 23 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $377.85 up to $519.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.506. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG. ; Moderna, Inc. ; and Entrada Therapeutics, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .